What is the clinical evidence from this study?

Study design: Review. Population: Diabetes mellitus. Intervention: Antithrombotic therapies.

What does this research mean for the field?

Diabetes mellitus induces platelet and endothelial dysfunction and impairs fibrinolysis, creating a prothrombotic milieu that increases cardiovascular risk despite current antithrombotic therapies. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 18, 2023International Journal of Molecular SciencesOpen Access

The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk

View Full Paper

Ask AI

Bookmark

Key result

Diabetes drives a prothrombotic state via platelet hyperreactivity and hypofibrinolysis, supporting targeted antithrombotic therapy.

Why the study?

Current antithrombotic therapies in diabetes remain largely similar to those for patients without diabetes, leading to high rates of treatment failure and increased bleeding risks.

Design

Narrative review

Authors

NSNawaz Z. SafdarLeeds Teaching Hospitals NHS Trust NKNoppadol KietsirirojeUniversity of Leeds RARamzi AjjanVascular Medicine

Discussion

Member takes

Implication

Does not support changing antithrombotic regimens in diabetes; leaves open targeted therapies pending prospective trials.

Structured PICO

Population

Individuals with diabetes mellitus (T1D and T2D) at risk of or with established cardiovascular/atherothrombotic disease

Intervention

Antithrombotic therapies (including aspirin, P2Y12 inhibitors, factor Xa inhibitors) and novel therapeutic targets (PAR-1, GPVI, antifibrinolytic proteins)

This review outlines the mechanisms of platelet dysfunction and hypofibrinolysis in diabetes, emphasizing the need for tailored antithrombotic therapies to mitigate the high residual risk of atherothrombotic events.

Limitations

Current 'one size fits all' approach to antiplatelet therapy is inadequate for patients with diabetes
Lack of effective thrombosis and bleeding risk scores to optimize therapy

Cite This Study

Safdar et al. (2023) conducted a review in Diabetes mellitus. Antithrombotic therapies was evaluated. Diabetes induces a prothrombotic state via platelet hyperreactivity and hypofibrinolysis, highlighting the need for novel, targeted antithrombotic therapies to reduce cardiovascular risk.

synapsesocial.com/papers/6a1bfc784ebd09f3dfa94c55 https://doi.org/10.3390/ijms242015328

View Full Paper

Ask AI

Bookmark

The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider